title: Molecular-targeted nanotherapies in cancer: enabling treatment specificity.
abstract: Chemotherapy represents a mainstay and powerful adjuvant therapy in the treatment of cancer. The field has evolved from drugs possessing all-encompassing cell-killing effects to those with highly targeted, specific mechanisms of action; a direct byproduct of enhanced understanding of tumorigenic processes. However, advances regarding development of agents that target key molecules and dysregulated pathways have had only modest impacts on patient survival. Several biological barriers preclude adequate delivery of drugs to tumors, and remain a formidable challenge to overcome in chemotherapy. Currently, the field of nanomedicine is enabling the delivery of chemotherapeutics, including repositioned drugs and siRNAs, by giving rise to carriers that provide for protection from degradation, prolonged circulation times, and increased tumor accumulation, all the while resulting in reduced patient morbidity. This review aims to highlight several innovative, nanoparticle-based platforms with the potential of providing clinical translation of several novel chemotherapeutic agents. We will also summarize work regarding the development of a multistage drug delivery strategy, a robust carrier platform designed to overcome several biological barriers while en route to tumors.
authors.affiliation: Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA.
authors.forename: Elvin
authors.initials: E
authors.lastname: Blanco
authors.forename: Angela
authors.initials: A
authors.lastname: Hsiao
authors.forename: Guillermo U
authors.initials: GU
authors.lastname: Ruiz-Esparza
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Landry
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
authors.forename: Mauro
authors.initials: M
authors.lastname: Ferrari
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy*; D034741:RNA, Small Interfering / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering
references.citation: Nat Rev Clin Oncol. 2011 Jun;8(6):319-20
references.pmid: 21556024
references.citation: Biomaterials. 2009 May;30(13):2440-8
references.pmid: 19215978
references.citation: Cancer. 2010 Oct 1;116(19):4597-604
references.pmid: 20572031
references.citation: Chemphyschem. 2010 Apr 6;11(5):1029-35
references.pmid: 20162656
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: J Control Release. 2008 Jul 14;129(2):107-16
references.pmid: 18486981
references.citation: Cancer Res. 2010 May 15;70(10):3896-904
references.pmid: 20460521
references.citation: Curr Opin Mol Ther. 2003 Oct;5(5):547-52
references.pmid: 14601525
references.citation: Pharm Res. 2009 Jan;26(1):235-43
references.pmid: 18712584
references.citation: Clin Pharmacokinet. 2003;42(5):419-36
references.pmid: 12739982
references.citation: Br J Haematol. 2010 Aug;150(4):438-45
references.pmid: 20618337
references.citation: Cancer Res. 2010 May 1;70(9):3687-96
references.pmid: 20430760
references.citation: Nat Rev Cancer. 2005 Oct;5(10):761-72
references.pmid: 16175177
references.citation: Nat Nanotechnol. 2007 Dec;2(12):751-60
references.pmid: 18654426
references.citation: Exp Biol Med (Maywood). 2009 Feb;234(2):123-31
references.pmid: 19064945
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Endocr Relat Cancer. 2008 Jun;15(2):499-510
references.pmid: 18509002
references.citation: Mol Pharm. 2009 May-Jun;6(3):659-68
references.pmid: 19267452
references.citation: J Clin Oncol. 1997 Feb;15(2):653-9
references.pmid: 9053490
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11832-7
references.pmid: 17609380
references.citation: Cancer Invest. 2001;19(4):424-36
references.pmid: 11405181
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1251-9
references.pmid: 16489081
references.citation: Clin Cancer Res. 2002 Apr;8(4):1172-81
references.pmid: 11948130
references.citation: Annu Rev Med. 2004;55:61-95
references.pmid: 14746510
references.citation: Nat Nanotechnol. 2008 Mar;3(3):151-7
references.pmid: 18654487
references.citation: Nat Rev Cancer. 2011 Aug 18;11(9):657-70
references.pmid: 21850037
references.citation: Nanomedicine (Lond). 2010 Feb;5(2):181-92
references.pmid: 20148631
references.citation: Sci Transl Med. 2011 Jan 5;3(64):64ra2
references.pmid: 21209412
references.citation: Oncogene. 2000 Dec 27;19(56):6550-65
references.pmid: 11426640
references.citation: Expert Rev Anticancer Ther. 2011 Mar;11(3):333-49
references.pmid: 21417849
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21
references.pmid: 17379663
references.citation: Nature. 2001 May 24;411(6836):494-8
references.pmid: 11373684
references.citation: Nat Nanotechnol. 2008 Mar;3(3):131-2
references.pmid: 18654480
references.citation: Trends Biotechnol. 2010 Apr;28(4):181-8
references.pmid: 20079548
references.citation: Pharmacol Res. 2010 Aug;62(2):150-65
references.pmid: 20117211
references.citation: Anticancer Agents Med Chem. 2012 Feb;12(2):114-22
references.pmid: 21864231
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Mol Pharm. 2011 Dec 5;8(6):2101-41
references.pmid: 21974749
references.citation: Neoplasia. 2009 Aug;11(8):720-31
references.pmid: 19649202
references.citation: J Control Release. 2007 Oct 8;122(3):365-74
references.pmid: 17574288
references.citation: J Biomed Mater Res A. 2010 Sep 15;94(4):1236-43
references.pmid: 20694990
references.citation: Am J Clin Oncol. 2010 Apr;33(2):186-95
references.pmid: 19675448
references.citation: Folia Histochem Cytobiol. 2004;42(4):221-7
references.pmid: 15704648
references.citation: Breast Cancer Res. 2009;11(4):207
references.pmid: 19664181
references.citation: J Control Release. 2010 Jan 4;141(1):13-21
references.pmid: 19686789
references.citation: Nat Rev Clin Oncol. 2010 Sep;7(9):485-6
references.pmid: 20798696
references.citation: J Control Release. 2010 Feb 15;141(3):320-7
references.pmid: 19874859
references.citation: J Cancer Res Clin Oncol. 2010 Feb;136(2):267-74
references.pmid: 19693537
references.citation: Ann Oncol. 2011 Sep;22(9):1939-1947
references.pmid: 21289366
references.citation: Pharm Res. 2011 Dec;28(12):3069-78
references.pmid: 21879387
references.citation: Breast. 2010 Oct;19(5):333-8
references.pmid: 20185313
references.citation: Nature. 1998 Feb 19;391(6669):806-11
references.pmid: 9486653
references.citation: Nature. 2010 Apr 15;464(7291):1067-70
references.pmid: 20305636
references.citation: Cancer J. 2008 May-Jun;14(3):170-7
references.pmid: 18536556
references.citation: Cancer Treat Res. 2000;103:57-75
references.pmid: 10948442
references.citation: Nat Rev Cancer. 2008 Jun;8(6):473-80
references.pmid: 18469827
references.citation: Mol Cancer. 2008 Oct 23;7:82
references.pmid: 18947424
references.citation: Breast Cancer Res Treat. 2008 Mar;108(2):241-50
references.pmid: 17476588
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3366-79
references.pmid: 20530283
references.citation: BMC Cancer. 2011 Aug 16;11:354
references.pmid: 21846341
references.citation: Adv Enzyme Regul. 2001;41:189-207
references.pmid: 11384745
references.citation: Nat Rev Cancer. 2005 Mar;5(3):161-71
references.pmid: 15738981
references.citation: Biomaterials. 2010 Jul;31(20):5436-44
references.pmid: 20409581
references.citation: Mol Cancer Ther. 2011 Oct;10(10):1909-17
references.pmid: 21859842
references.citation: Pharm Res. 2007 Jun;24(6):1029-46
references.pmid: 17385025
references.citation: J Biol Chem. 2000 Feb 25;275(8):5416-24
references.pmid: 10681517
references.citation: J Natl Cancer Inst. 2011 Jan 19;103(2):87-9
references.pmid: 21191114
references.citation: Nat Rev Drug Discov. 2004 May;3(5):391-400
references.pmid: 15136787
references.citation: J Control Release. 2006 May 15;112(2):229-39
references.pmid: 16545478
references.citation: Mol Oncol. 2011 Dec;5(6):492-503
references.pmid: 22071376
references.citation: Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-1240
references.pmid: 18495291
references.citation: Clin Transl Oncol. 2011 Jul;13(7):485-98
references.pmid: 21775276
references.citation: J Clin Oncol. 2011 Feb 20;29(6):747-54
references.pmid: 21079135
references.citation: Int J Pharm. 2011 Nov 25;420(1):111-7
references.pmid: 21856392
references.citation: Nat Rev Clin Oncol. 2009 Oct;6(10):587-95
references.pmid: 19787002
references.citation: Nanomedicine. 2011 Dec;7(6):955-64
references.pmid: 21453789
references.citation: Ann Oncol. 2002 Jun;13(6):910-8
references.pmid: 12123337
references.citation: Adv Drug Deliv Rev. 2001 Mar 23;47(1):113-31
references.pmid: 11251249
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077